摘要:
The present invention relates to a compound represented by the formula (I) or (I′): wherein each symbol is as defined in the specification, or a salt thereof, and a PI3K and(or) mTOR inhibitor containing the compound or a prodrug thereof.
摘要:
A quinoxalinone derivative of the formula (I): or a pharmaceutically acceptable salt or ester thereof, wherein; X is NH, S or the like; Y is O or the like; the partial structure is, for example, the formula: B1, B2, . . . , Bn−1 and Bn, (in which n is 4, 5 or 6) are each independently CH, N or the like; B′1, B′2, . . . , B′n−1 and B′n (in which n is 4, 5 or 6) are each independently hydrogen or the like; and R is hydrogen, lower alkyl or the like.
摘要:
The present invention intends to find out a gene participating in addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genus Pichia and provide a means of controlling the same. The present invention also intends to provide a process for producing a protein with reduction of an acidic sugar chain by using the thus controlled yeast strain belonging to the genus Pichia. Namely, the present invention includes a protein participating in the addition of mannose phosphate to a sugar chain of a glycoprotein; a gene coding this protein; a mutant of this gene; a vector carrying the mutant gene; a yeast strain belonging to the genus Pichia having been transformed by this vector; a process for producing a protein with reduction of an acidic sugar chain by using the transformed yeast strain; and a glycoprotein thus produced.
摘要:
This invention provides compounds of formula IA or IB: wherein HY, R1, R2, and G1, are as described in the specification. The compounds are inhibitors of VPS34 and/or PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
摘要:
The present invention intends to find out a gene participating in addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genus Pichia and provide a means of controlling the same. The present invention also intends to provide a process for producing a protein with reduction of an acidic sugar chain by using the thus controlled yeast strain belonging to the genus Pichia. Namely, the present invention includes a protein participating in the addition of mannose phosphate to a sugar chain of a glycoprotein; a gene coding this protein; a mutant of this gene; a vector carrying the mutant gene; a yeast strain belonging to the genus Pichia having been transformed by this vector; a process for producing a protein with reduction of an acidic sugar chain by using the transformed yeast strain; and a glycoprotein thus produced.
摘要:
The present invention intends to find out a gene participating in addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genus Pichia and provide a means of controlling the same. The present invention also intends to provide a process for producing a protein with reduction of an acidic sugar chain by using the thus controlled yeast strain belonging to the genus Pichia. Namely, the present invention includes a protein participating in the addition of mannose phosphate to a sugar chain of a glycoprotein; a gene encoding this protein; a mutant of this gene; a vector carrying the mutant gene; a yeast strain belonging to the genus Pichia having been transformed by this vector; a process for producing a protein with reduction of an acidic sugar chain by using the transformed yeast strain; and a glycoprotein thus produced.
摘要:
This invention relates to novel compounds represented by the general formula [I]: (wherein, R1 and R4 are the same or different, and represent hydrogen atoms, lower alkyl groups or the like; R2 and R3 are the same or different, and represent lower alkoxy groups or lower alkyl groups; R5 represents a lower alkyl group or aralkyl group optionally having substituent(s); R6 represents a hydrogen atom or a lower alkyl group; X represents O, S or NH; m represents an integer of 0 to 3; n represents an integer of 0 or 1; and Ar represents a phenyl group or heteroaryl group optionally having substituent(s)). The compounds of the invention have an antagonistic action on orexin receptors, and are useful for treatment of appetite abnormality, obesity, sleeping disorder or the like.
摘要翻译:本发明涉及由通式[I]表示的新化合物:(其中R 1和R 4相同或不同,表示氢原子,低级烷基等; R 2和 R 3相同或不同,表示低级烷氧基或低级烷基; R 5表示任选具有取代基的低级烷基或芳烷基; R 6表示氢原子或低级烷基 烷基; X表示O,S或NH; m表示0至3的整数; n表示0或1的整数; Ar表示任选具有取代基的苯基或杂芳基) 本发明对食欲肽受体具有拮抗作用,可用于治疗食欲异常,肥胖,睡眠障碍等。
摘要:
A rectifying section 2, and a DCDC converter 3 which lowers an input DC voltage and then outputs the voltage are disposed between an AC generator 1 and a load 4. When the output voltage Vt of the AC generator 1 is gradually lowered with starting from E0, the output power P is increased, and is maximum at Vt=V12. When the output voltage Vt is further lowered, the output power P is reduced. As an operating point at which the same output power P is obtained, there are a point of Vt=V11, and that of Vt=V13. The operation of the DCDC converter 3 is controlled so as to operate at the point of Vt=V13 where the output current I is lower.
摘要:
The device of the present invention is used to measure the intensity of a disturbing wave and measures an average value of impulsive noise. The invention permits accurate and short-time measurements. Impulsive noise, which is input via a variable attenuator, a frequency converter, an intermediate-frequency amplifier and a band-pass filter of a 9 or 120 kHz pass frequency, is provided to a linear detector. The detected output is applied to a low-pass filter which is composed of CR elements and whose cut-off frequency is tens of kilohertz. By the low-pass filter, the peak value of the detected output is lowered and its width is increased. The filter output is converted by an A-D converter to a digital signal. Digital values at respective sample points in the digital signal of one frame are added by an arithmetic circuit, and the added value is divided by the number of samples to obtain an average value, which is displayed.
摘要:
A human prourokinase mutant in which the entire or a partial epidermal growth factor domain of human prourokinase is deleted or a partial epidermal growth factor domain of human prourokinase is replaced by one or more different amino acid residues, said mutant having a longer blood half-life than naturally occurring human prourokinase while retaining prourokinase enzymatic activity. In this human prourokinase mutant the region selected from the group consisting of: (a) from asparagine (10) to cysteine (42); (b) from asparagine (10) to aspartic acid (45); and (c) from asparagine (10) to threonine (49) is missing.